Related Experiment Video
Updated: Sep 28, 2026
Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib
Published on: April 3, 2026
Imatinib mesylate therapy in patients with gastrointestinal stromal tumors and impaired liver function
Sebastian Bauer1, Volker Hagen, Hermann J Pielken
1Innere Klinik und Poliklinik (Tumorforschung), Universitätsklinikum Essen, Westdeutsches Tumorzentrum, 45122 Essen, Germany. sebastian@uni-essen.de
Abstract:
Hepatic and peritoneal metastases are the most frequent metastatic lesions in patients with gastrointestinal stromal tumors (GIST), and may result in intra- or extrahepatic cholestasis and altered drug metabolism. While the tyrosine kinase inhibitor imatinib, which has been recently shown to represent the treatment of choice for GIST, is primarily metabolized by the liver, data on the pharmacokinetics and the tolerability of imatinib in patients with increased cholestasis parameters are not yet available. We here report on two patients who received imatinib in the presence of increased bilirubin and/or cholestasis parameters. With a follow-up duration of 3-4 months, we observed no toxicities outside of well-known side effects including some degree of myelosuppression and fluid retention. This report may aid in the decision of imatinib being given under close surveillance to this kind of patients.
Insights
This study examined imatinib treatment in gastrointestinal stromal tumor (GIST) patients with cholestasis. Imatinib was tolerated, showing manageable side effects in these specific GIST patients.
Area of Science:
- Oncology
- Pharmacology
- Hepatology
Background:
- Gastrointestinal stromal tumors (GIST) frequently metastasize to the liver and peritoneum.
- Metastases can cause cholestasis and alter drug metabolism, complicating treatment.
- Imatinib is a primary treatment for GIST, but its use in cholestatic patients is understudied.
Observation:
- Two GIST patients with elevated bilirubin and/or cholestasis parameters received imatinib.
- Treatment duration was 3-4 months.
- Patients were monitored for pharmacokinetics and tolerability.
Findings:
- No new toxicities were observed beyond known imatinib side effects.
- Observed side effects included myelosuppression and fluid retention.
- The drug appeared to be tolerated in these patients.
Implications:
- Imatinib may be a viable treatment option for GIST patients with cholestasis.
- Close patient surveillance is recommended when administering imatinib in cases of increased cholestasis.
- Further research is needed to fully understand imatinib pharmacokinetics in this population.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...